In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016-19).

Ceftobiprole continues to exhibit potent and broad-spectrum activity against Gram-positive and Gram-negative clinical isolates from Europe, and as expected, with a slight north-to-south and west-to-east susceptibility gradient.